首页> 外文期刊>Molecular pharmaceutics >Synergistic Antitumor Potency of a Self-Assembling Peptide Hydrogel for the Local Co-delivery of Doxorubicin and Curcumin in the Treatment of Head and Neck Cancer
【24h】

Synergistic Antitumor Potency of a Self-Assembling Peptide Hydrogel for the Local Co-delivery of Doxorubicin and Curcumin in the Treatment of Head and Neck Cancer

机译:自组装肽水凝胶的协同抗肿瘤效力,用于局部共同递送的多柔比星和姜黄素治疗头颈癌

获取原文
获取原文并翻译 | 示例
           

摘要

Combination therapy has been conferred with manifold assets leveraging the synergy of different agents to achieve a sufficient therapeutic outcome with lower administered drug doses and reduced side effects. The therapeutic potency of a self-assembling peptide hydrogel for the co-delivery of doxorubicin and curcumin was assessed against head and neck cancer cells. The dual loaded peptide hydrogel enabled control over the rate of drug release based on drug's aqueous solubility. A significantly enhanced cell growth inhibitory effect was observed after treatment with the combination drug-loaded hydrogel formulations compared to the respective combination drug solution. The synergistic pharmacological effect of selected hydrogel formulations was further confirmed with enhanced apoptotic cell response, interference in cell cycle progression, and significantly altered apoptotic/anti-apoptotic gene expression profiles obtained in dose levels well below the half-maximal inhibitory concentrations of both drugs. The in vivo antitumor efficacy of the drug-loaded peptide hydrogel formulation was confirmed in HSC-3 cell-xenografted severe combined immunodeficient mice and visualized with mu CT imaging. Histological and terminal deoxynucleotidyl transferase dUTP nick end labeling assay analyses of major organs were implemented to assess the safety of the topically administered hydrogel formulation. Overall, results demonstrated the therapeutic utility of the dual drug-loaded peptide hydrogel as a pertinent approach for the local treatment of head and neck cancer.
机译:结合治疗已赋予利用不同剂量的协同作用的歧管资产赋予歧管,以达到足够的治疗药物剂量和减少副作用。对颈部癌细胞评估了对多码毛蛋白和姜黄素共同递送的自组装肽水凝胶的治疗效力。基于药物的含水溶解度,双载肽水凝胶能够控制药物释放速率。与各种组合药物溶液相比,在用组合药物加载的水凝胶制剂处理后观察到显着增强的细胞生长抑制效果。通过增强的凋亡细胞响应,细胞周期进展的干扰进一步证实了所选水凝胶制剂的协同药理作用,并且在剂量水平下显着改变了凋亡/抗凋亡基因表达谱,良好低于两种药物的半最大抑制浓度。在HSC-3细胞 - 异种移植的严重组合免疫缺陷小鼠中证实了药物负载肽水凝胶制剂的体内抗肿瘤效果,并用MU CT成像进行了可视化。实施主要器官的组织学和末端脱氧核苷酸转移酶DUTP缺口末端标记测定分析,以评估局部施用的水凝胶制剂的安全性。总体而言,结果证明了双重药物肽水凝胶的治疗效用作为局部治疗头颈癌的相关方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号